NurOwn Found Safe, Shows Promise in Phase 2 Trial for Progressive MS
NurOwn, a stem cell therapy being developed by BrainStorm Cell Therapeutics, showed a good safety profile among people with progressive forms of multiple sclerosis (MS) in an open-label Phase 2 clinical trial, according to new data. The data show the experimental therapy also was associated with promising effects on…